Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an announcement.
Venus Medtech (Hangzhou) Inc. announced a proposed issuance of convertible bonds up to RMB200 million under a general mandate. The proceeds are intended to accelerate product pipeline development, optimize capital structure, and supplement working capital. The issuance will not require further shareholder approval and is contingent upon certain conditions, including stock exchange listing approval.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company based in the People’s Republic of China, operating in the medical technology industry. The company focuses on the development and commercialization of innovative heart valve products and related medical devices, aiming to address unmet clinical needs in cardiovascular health.
YTD Price Performance: -60.14%
Average Trading Volume: 41,208,580
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$807.1M
See more insights into 2500 stock on TipRanks’ Stock Analysis page.